Shanghai Medicilon Inc.

Recently, Suzhou Jingye Medicine & Chemical (Jingye) successfully obtained the "Notice of Approval for Chemical   Active Pharmaceutical Ingredient (API)   Marketing Application" issued by the National Medical Products Administration (NMPA) for its raw material of Clomipramine hydrochloride. This significant achievement not only affirms Jingye's profound capabilities in the research and development of APIs, but also recognizes its rigorous production processes and quality management system, which strive for excellence.   Meanwhile, as a partner of Jingye, Medicilon has provided services such as API process development and solvent substitution.  This also demonstrates Medicilon's professionalism and reliability in the field of API services.  Following Jingye's successful transformation and the achievement of its first API going to market, Medicilon has specially invited Mr. Weidong Yuan, the responsible person from Jingye, to provide an in-depth analysis and s...

On June 20 t h , the 4 th   Pharmaceutical Innovation Awards ceremony, organized by the Securities Times under People's Daily, was unveiled in Shanghai. Medicilon was honored with the "Top Ten Drug Innovation Service Institutions of the Year" at the 4 th  Pharmaceutical Innovation Awards for its innovative capabilities and service quality in the field of biopharmaceutical preclinical R&D services. This marks the third consecutive year that Medicilon has won this prestigious award. This achievement not only serves as a profound recognition of its two decades of continuous contributions to drug development but also stands as the best testament to its spirit of innovation. About Pharmaceutical Innovation Awards The "Pharmaceutical Innovation Award" is a highly influential event within the industry, organized by Securities Times, an authoritative financial and securities media outlet under the People's Daily. The award aims to recognize companies and individ...

  On June 24, 2024, Medicilon announced that its wholly-owned subsidiary, Medicilon Preclinical Research  (MRP), has officially signed a collaboration agreement with Hetuo Innovation (Hetuo).  The two parties will engage in comprehensive and in-depth collaboration in multiple fields, including animal electrocardiogram diagnostics and personnel training, as well as animal ophthalmic disease diagnosis and model establishment, to jointly promote the development of innovative drugs. Complementary advantages drive improvement; working together to empower new capabilities  Supporting the development of cardiovascular and ophthalmic disease drugs Hetuo is a CRO specializing in preclinical pharmacodynamic evaluation, focusing on translational medicine platform technologies, and actively promoting the industrialization of medicine.  The company adheres to GLP standards, implementing scientific management of projects to ensure the authenticity, accuracy/scientific integri...

Recently, the Analytical Testing Center of Shanghai Medicilon Inc. (Medicilon) successfully passed the on-site assessment by the China National Accreditation Service for Conformity Assessment (CNAS).  This marks that Medicilon's Analytical Testing Center has achieved international recognition standards for its testing results and service quality, laying a solid foundation for the company's continuous deepening in the biopharmaceutical R&D field and expansion into international markets in the future. During this assessment, the CNAS expert team conducted a comprehensive and in-depth inspection of Medicilon's laboratory, covering several key aspects such as the quality manual, procedural documents, operational guidelines, on-site instruments and equipment, and experimental operations.  Following a series of rigorous and professional review procedures, the expert team unanimously concluded that Medicilon's laboratory met the highest requirements of international standa...

  On July 4 th , the 2024 International Pharmaceutical Services Industry Innovation and Development Conference, along with the 9 th   Summit for China Pharmaceutical R&D Innovation, was grandly held at the Xiongan Convention and Exhibition Center.  At the conference, the highly anticipated "2024 China Pharmaceutical R&D Strength Ranking" was announced.  Shanghai Medicilon Inc. (Medicilon) stood out among hundreds of pharmaceutical enterprises and was honored with the " Top 20 Chinese R&D CRO Enterprises in 2024" award. About the Top 20 Chinese R&D CRO Enterprises in 2024 The "2024 China Pharmaceutical R&D Strength Ranking" is selected by the Organizing Committee of the China Pharmaceutical R&D Innovation Summit and the Expert Committee of the 2024 China Pharmaceutical R&D Strength Ranking. It aims to uncover and drive innovative forces in pharmaceutical R&D, encourage and recognize enterprises making significant contributio...

  On July 4 th , the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.  The event was attended by Fang Zou, the Executive Vice President of the Shanghai Overseas Returned Scholars Association, along with officials from the Liaison Department and cadres from the United Front Work Department of the Pudong New Area District Committee. At the beginning of the event, the Dutch PhD delegation eagerly visited Medicilon's laboratory, where they closely observed the advanced equipment and innovative technologies in the field of new drug development. They witnessed the efficient operation of state-of-the-art instruments and the meticulous and scientific approach of the research project teams in their daily work. This immersive experience conveyed the vitality and boundless promise inherent in biopharmaceutic...

On June 25 th , the "Resilience and Innovation: 2024 Mithink Summit" hosted by Menet, a subsidiary of the Southern Institute of Medical Economics under the National Medical Products Administration, released the 2023 China Pharmaceutical Industry Top 100 Rankings lists.  Medicilon, with its outstanding R&D capabilities and continuous spirit of innovation, has once again topped the 2023 China CXO (including CDMO) Enterprise Top 20 List.  This is the sixth consecutive year that Medicilon has received this honor. Medicilon's sixth consecutive win of this honor not only represents the industry's authoritative recognition of its comprehensive biopharmaceutical preclinical R&D service platform, but also affirms its contributions to the pharmaceutical research and development field. About the China's Top 100 Pharmaceutical Industry List Series The "China's Top 100 Pharmaceutical Industry List Series" as an authoritative industry list, initiated and h...